Strengthen Credibility, Trust & Impact & Deliver Sustainable Reputation Communications Excellence For Pharma & Healthcare
08.30 Registration & Informal Networking
OPENING REMARKS
09.00 GIC Welcome & Morning Co-Chairs’ Opening Remarks
Duccio Manetti, Group Chief Communications & Government Affairs Officer, Kedrion Biopharma
Rachel James-Owens , Vice President Corporate Communications and Media Relations, Zealand Pharma
Leveraging AI in Strategic Communications to Drive Reach, Resonance and Impact
OPENING KEYNOTE
09.10 Harness AI Make Communication Functions More Operable, Provide Insights and Boost Cross-Functional Collaboration
- Go beyond the use of AI as just a time saving application and harness the strategic implementation of AI for communicators and its demonstrable business impact
- How is AI influencing the information landscape and what impact is that having on trust, credibility and perception in the pharma industry?
- Evolve or perish! Adapt to constantly changing AI developments and evolve alongside AI to keep pace with tech changes
Krysia Sommers, Head of Strategic and Executive Communications, Bayer
Effective Patient Partnerships
PANEL Q&A
09.30 Harness Patient Influence, New Channels & Shared Expertise to Shape Meaningful Partnerships & Deliver Demonstrable Impact
- Amplify patient voices and going beyond storytelling to build long-term relationships and trust between patients, patient groups and pharma companies
- Harness the rise of the patient as an influencer and maximise the value of collaborative relationships for greater reach through trusted voices
- Find the balance between the clinical expertise of pharma and the patients’ lived experience to promote co-creation and shared decision making
- How can Pharma and patients collaborate on campaign-led patient advocacy and deliver tangible examples of impactful patient partnerships?
Kylie Cuff, Global Communications, Vaccines, GSK
Gabor Purman, Patient Advocacy Director, Kyowa Kirin
Lisa Timothy, Head of Public Affairs & Patient Advocacy, Takeda
Pia Beltrao Hansen, Senior Director, Head of Commercial Communications, Ascendis Pharma
Disease Awareness
KEYNOTE
10.00 Adapt Disease Awareness to Changing Patient Behaviours While Tackling Misinformation with Trusted & Inclusive Communications
- Make use of practical approaches to disease awareness with integrated campaigns that come together as a chorus to amplify impact
- Identify the changes in the way patients interact with healthcare and adapt approaches to disease awareness accordingly
- How can organisations tackle the rise of misinformation with meaningful contributions to patient education?
- Enforce allyship across disease areas that recognises the diversity of patient voice and go beyond box-ticking
Alessandra Fonseca, Global External Communication Director, Kedrion Biopharma
Geopolitics: Agility in Uncertainty
PANEL Q&A
10:20 Balance Agility & Messaging Consistency As Geopolitical Forces Reshape Reputation & Drive Durable Organisational Reputation
- How can pharma companies preserve identity under the pressure of political polarisation and remain a trusted voice amongst patients?
- How can organisations develop comms strategies that are agile, flexible and durable enough to withstand volatile external conditions?
- How can teams communicate strategically during times of tension, balancing values, business interested and external stakeholders into a consistent narrative?
Alexander Kandt, VP – Global Communications, Takeda
Rene Rust, Head of Corporate Communications and Government Affairs, Almirall
Lucie Sabikova, Head of Communications MCO Eastern Europe, Takeda
Diana Trojanus, Communications Director, EMEA Region, Merz Aesthetics
10.50 Bonus Session; Reserved For Exclusive Conference Partner
11.20 Morning Refreshment Break with Informal Networking
Social Media & Channel Mix
KEYNOTE
11.50 Balance Influence, Compliance & Authenticity in a Rapidly Changing Social Environment
- How can industry navigate communications with stakeholders across social media platforms whilst ensuring compliance across all channels?
- Nurture deeper connections on social media and showcase the humanity behind pharma and healthcare
- How can organisations take control of brand narratives and shape external perception across complex channels and platforms?
Katie Vickers, Social Media & Digital Communications Manager, AbbVie
12.30 Lunch Break & Informal Networking
13.00 Peer To Peer Discussion Zones
A) Internal Comms
Kylie Cuff, Global Communications, Vaccines , GSK
B) AI as a Tool in Comms
Laura Chamley, Senior Director Public Affairs, Gilead Sciences
C) Strategic Role of Comms
Mark Grossien, Head of Strategic Communications, Sandoz
D) Strategic Role of Comms
Xenia Wierzbicki, Scientific Communications & Engagement Associate Director, Astrazeneca
13.30 Afternoon Co-Chairs’ Opening Remarks
Marina Moustaka, Director, International Medical Communications, Abbvie
Karen Borrer, Head of Communications, UCB
Evolving Stakeholder Ecosystems
PANEL Q&A
13:40 Navigate Complex Stakeholder Landscapes with Cohesive Strategies that Drive Collaboration & Trust
- How can teams leverage integrated communication plans to promote collaboration with different stakeholder groups?
- Streamline communications through multiple channels to meet the needs of complex stakeholder audiences
- Maximise the impact of comms strategies across key audiences and build trust in a changing environment
Chiara Antoniucci, Global External & Internal Communication Director, Angelini Pharma
Eoin Weldon, Head of EMEA Communications, Merck Life Sciences
Katherine Jordan, Senior Director for Corporate Affairs, Novo Nordisk
Misinformation, Trust & Credibility
KEYNOTE
14.10 Turn Insights into Action: Measurable Strategies To Combat Misinformation & Build Lasting Trust Across Stakeholder Audiences
- How can organisations become a trusted tone of voice in the age of misinformation and scepticism around healthcare products and services?
- How can the healthcare system shape perception and build brand credibility in an era where reactionary or misinformed information travels at lightening speed?
- How can industry contribute to the prevention of misinformation, and not just intervention when it emerges?
Robert Ede, Senior Director and Head of Corporate Affairs, Lilly
Building Reputation – ABPI’s Value of Industry Campaign
KEYNOTE
14.30
Andy Collier, Senior Policy Manager – Reputation, ABPI
Measuring Impact in Pharma Comms
KEYNOTE
14.50 Turn Insights into Action: Measurable Strategies To Combat Misinformation & Build Lasting Trust Across Stakeholder Audiences
- How can organisations become a trusted tone of voice in the age of misinformation and scepticism around healthcare products and services?
- How can the healthcare system shape perception and build brand credibility in an era where reactionary or misinformed information travels at lightening speed?
- How can industry contribute to the prevention of misinformation, and not just intervention when it emerges?
Roman Godau, Senior Manager Impact Valuation, Novartis
15.10 Afternoon Refreshment Break with Informal Networking
Reputation Management
KEYNOTE
15.40 Safeguard Trust Through Proactive, Coordinated & Data Informed Reputation Management
- How can organisations identify early signals of reputational risk and develop proactive strategies to mitigate issues?
- Leverage data and stakeholder intelligence to inform reputation strategy and guide decision making
- How can professionals proactively protect organisational reputation in such a fast-paced and heavily scrutinised healthcare environment?
Marco Gerometta, Communications Director – Global Clinical Operations, R&D, GSK
Compliance without Constraint
KEYNOTE
16.00 Create Flexible, Compliant Communication Strategies That Can Adapt To Evolving Policy Demands
- How can teams ensure alignment and compliance across cross-market communications?
- Dive into the role of communications in shaping and responding to policy developments across healthcare systems
- Stay ahead of shifting regulations by building agile processes that can respond to change without compromising quality or integrity
16.20 Afternoon Co-Chairs’ Closing Remarks & End of Conference
